Bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 139-143

  Pollina, L ^a   Pacini, F ^b   Fontanini, G ^a   Vignati, S ^a   Bevilacqua, G ^a   Basolo, F ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Institute of Endocrinology   (Italy)

Author keywords

bcl 2; Immunohistochemistry; p53; Thyroid cancer

Indexed keywords

ANTIBODY; CYCLINE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL FEATURE; EPITHELIUM; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; MUTATION; PRIORITY JOURNAL; PROGNOSIS; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICLE; TISSUE SECTION; UNDIFFERENTIATED CARCINOMA;

EID: 0029671093     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.26     Document Type: Article

References (27)

1. BASOLO F, PINCHERA A, FUGAZZOLA L, FONTANINI G, ELISEI R, ROMEI C AND PACINI F. (1994). Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur. J. Cancer, 30, 171-174.
2. BOURHIS J, BOSO J, WILSON GD, BRESSAC B, TALBOT M, LERIDANT AM, DENDALE R, JANIN N, ARMAND JP, LUBOINSKI B, MALAISE EP, WILBAULT P AND ESCHWEGE F. (1994). Correlation between p53 gene expression and tumour-cell proliferation in oropharingeal cancer. Int. J. Cancer, 57, 458-462.
3. CATTORETTI G, BECKER MH, KEY G, DUCHROW M, SCHLUTER C, GALLE J AND GERDES J. (1992). Monoclonal antibodies against recombinant part of Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168, 357-363.
4. CORDELL JL, FALINI B, ERBER WN, GHOSH AK, ABDUL-AZIZ Z, MACDONALD S, PULFORD KAF, STEIN H AND MASON D. (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem., 32, 219-229.
5. DOBASHI Y, SAKAMOTO A, SUGIMURA H, MERNYEI M, MORI M, OYAMA T AND MACHINAMI R. (1993). Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am. J. Surg. Pathol., 17, 375-381.
6. FAGIN JA, MATSUO K, KARMAR A, CHEN DL, TANG SH AND KOEFFLER HP. (1993). High prevalence of mutation of p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest, 91, 179-184.
7. HAY ID. (1990). Papillary thyroid carcinoma. Endocrinol. Metab. Clin. North Am., 19, 554-557.
8. HOCKENBERY D, NUNEZ G, MILLIMAN C, SCHREIBER RD AND KORSMEYER SJ. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334-336.
9. HOCKENBURY DM, ZUTTER M, HICHEY W, NAHAM M AND KORSEMEYER SJ. (1991). Bcl-protein is topographically restricted in tissue characterized by apoptotic cell death. Proc. Natl Acad. Sci. USA, 88, 6961-6965.
10. HOLM R AND NESLAND JM. (1994). Retinoblastoma and p53 tumor suppressor gene protein expression in carcinomas of the thyroid gland. J. Pathol., 172, 267-272.
11. HSU S-M, RAINE L AND FANGER HA. (1981). A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol. 75, 734-738.
12. ITO T, SEYAMA T AND MIZUNO T. (1992). Unique association of p53 mutation with undifferentiated but not differentiated carcinomas of the thyroid gland. Cancer Res., 52, 1369-1697.
13. ITO T, SEYAMA T, MIZUNO T, TSUYAMA N, HAYASHI Y, DOHI K, NAKAMURA N AND AKIYAMA M. (1993). Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J. Cancer Res., 84, 526-531.
14. LEVINE AJ, PERRY ME, CHANG A, SILVER A, DITTMER D, WU M AND WELSH D. (1994). The 1993 Walter Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer, 69, 409-416.
15. MERCER WE, AVIGNOLO C AND BASERGA R. (1984). Role of p53 protein in cell proliferation as studied by microinjection on monoclonal antibodies. Mol. Cell. Biol., 4, 276-281.
16. MERLO GR, BERNARDI A, DIELLA F, VENESIO T, CAPPA APM, CALLAHAN R AND LISCIA D. (1993). In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with high S-phase index. Int. J. Cancer, 54, 531-535.
17. PACINI F, PINCHERA A, MANCUSI F, POLLINA L, FONTANINI G, BEVILACQUA G, CARTEI F, MICCOLI P AND BASOLO F. (1994). Anaplastic thyroid carcinoma: a retrospective clinical and immunohistochemical study. Oncol. Rep., 1, 921-925.
18. PIGNATELLI M, STAMP GWH, KAFIRI G, LANE D AND BODMER WF. (1992). Overexpression of p53 nuclear oncoprotein in colorectal adenomas. Int. J. Cancer, 50, 683-688.
19. PILOTTI S, COLLINI P, RILKE F, CATTORETTI G, DEL BO R AND PIEROTTI MA. (1994). Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J. Pathol., 172, 337-342.
20. RAFF MC, BARRES BA, BURNE JF, COLES HS, ISHIZAKI Y AND JACOBSON MD. (1993). Programmed cell death and the control of cell survival: lessons from the nervous system. Science, 262, 695-700.
21. REED JC. (1994). Bcl-2 and regulation of programmed cell death. J. Cell Biol., 124, 1-6.
22. SOARES P, CAMESELLE-TEIJEIRO J AND SOBRINHO-SIMOES M. (1994). Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology, 24, 205-210.
23. TSUJIMOTO Y, GORHAM J, COSSMAN J, JAFFE E AND CROCE CM. (1985). The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science, 299, 1390-1393.
24. TSUJIMOTO Y, IKEGAKI N AND CROCE CM. (1987). Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene, 2, 3-7.
25. VOLGELSTEIN B AND KINZLER KW. (1992). p53 function and dysfunction. Cell, 70, 523-526.
26. WYNFORD-THOMAS D. (1992). p53 in tumour pathology: can we trust immunocytochemistry?. J. Pathol., 166, 329-330.
27. YONISCH-ROUACH E, RESNITZKY D, LOTEM J, SACHS L, KIMCHI A AND OREN M. (1991). Wild-type p53 induces apoptosis of myeloid leukemyc cells that is inhibited by interleukin-6. Nature, 352, 345-347.